Industry News

Cue Biopharma in $374M-plus Merck immunotherapy pact

20/11/2017

After raising $26 million at the start of the year, cancer and autoimmune startup Cue Biopharma has ended the year with a potentially lucrative new deal with Merck.

More...

Scotland approves three new meds for NHS use

20/11/2017

The Scottish Medicines Consortium (SMC) has published new advice accepting three new medicines for use by NHS Scotland, offering patients new treatment options for soft tissue sarcoma, acromegaly and hepatitis C.

More...

Portable Transcranial Doppler Technology Can Accurately Measure Early Strokes

20/11/2017

Brain health technologist, Neural Analytics, Inc., is pointing at study results that say its transcranial doppler is 94% accurate in early identification if stroke.

More...

Medical devices could be key to the fight on antibiotic resistance

13/11/2017

Two medical devices developed by University of Birmingham researchers to help the fight against antibiotic resistance will be exhibited in the Superbugs: The Fight For Our Lives exhibition, which opens at the Science Museum in London on 9th November.

More...

NHS England, Roche come to agreement on Perjeta

13/11/2017

NHS England and Roche have agreed a confidential commercial agreement on the price of Perjeta for certain patients with breast cancer.

More...

Sanofi pays $40M, commits $765M more for preclinical MS drug

13/11/2017

Sanofi has committed up to $805 million to license multiple sclerosis drug PRN2246 from Principia Biopharma. The French Big Pharma is paying $40 million upfront to pick up the preclinical asset, with $765 million more to follow if it passes all the milestones that await.

More...

GlaxoSmithKline R&D chief Vallance to leave for government job: FT

06/11/2017

GlaxoSmithKline’s long-standing president of R&D, Patrick Vallance, is said to be standing down.

More...

AZ’ experimental asthma drug fails in Phase III

06/11/2017

An experimental therapy being developed by AstraZeneca and its biologics research and development arm MedImmune has failed to hit key targets in two Phase III trials.

More...

ObesityWeek™ 2017 Sees Ethicon Launching Bariatric Surgery App

06/11/2017

J&J device company Ethicon is partnering with J&J Health & Wellness Solutions to introduce a new digital platform and smartphone app. The idea is to offer resources and decision-making tools for patients considering weight loss surgery.

More...

High-dose Gilead/Nimbus NASH drug hits liver fat

30/10/2017

In new phase 2 data published today, Gilead says a higher dose of its NASH drug saw statistically significant reductions in liver fat, although a lower dose missed the mark.

More...

Biogen takes up option to co-develop Eisai AD drug

30/10/2017

Biogen and Eisai have expanded their existing collaboration agreement to develop and commercialise investigational therapies for Alzheimer’s Disease.

More...

J&J’s DePuy Synthes Launches Two MIS Spinal Fusion Surgery Devices

30/10/2017

As MIS gains traction and shows reduced complications compared to open surgery, DePuy Synthes is introducing two devices that are designed to simplify degenerative disc procedures.

More...

NICE nod for GSK’s ‘bubble baby syndrome’ gene therapy

24/10/2017

The National Institute for Health and Care Excellence has published draft guidance recommending GlaxoSmithKline’s gene therapy Strimvelis as an option for treating an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome.

More...

New Funding Will Fuel Claret Medical’s U.S. Plans for Sentinel® Cerebral Protection System

24/10/2017

Claret Medical® has closed a $14.5million funding round that it says will support market access programs for the Sentinel® Cerebral Protection System.

More...

AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data

24/10/2017

ADC Therapeutics has raised $200 million (€170 million), bringing its total haul up to $455 million. The antibody-drug conjugate (ADC) specialist will use the money to take its two lead hematological cancer assets through registrational trials. 

More...

Space Station Tech Behind New Surgical Robot Arm

12/10/2017

Canadian medtech company Synaptive Medical Inc., has released Modus V™, its second-generation, high-powered digital microscope. The interesting bit is the system’s surgical robotic arm, which is derived from Canadarm technology used on the International Space Station.

More...

US Cancer Therapy Provider Elects to Adopt Elekta as Complete Solution

12/10/2017

Radiation therapy products from Elekta are to be adopted by a US cancer care service as the complete solution for its radiation oncology needs, says the company.

More...

DePuy Synthes Unveils VIPER PRIME™ MIS Pedicle Screw System at EuroSpine

12/10/2017

DePuy Synthes unveiled its new VIPER PRIME™ System during this week’s EUROSPINE 2017 congress in Dublin, Ireland. The company describes the product as an innovative, Minimally Invasive Surgery (MIS) pedicle screw designed to simplify MIS spinal fusion surgery.

More...

Green Light for BioCardia Study Following Interim Safety Analysis

05/10/2017

Cardiovascular Regenerative therapies company, BioCardia tells us that the independent Data Safety Monitoring Board (DSMB) has indicated there were no significant safety concerns with the CardiAMP study results and recommended that the trial continue, as planned.

More...

UK MedTech on a Mission in California

05/10/2017

A group comprising UK clinicians and medical technology companies have been be visiting California this week (23-29 September 2017) in a bid to forge stronger relationships across the State.

More...

Pentax Medical Europe Unveils Unique Duodenoscope with Disposable Elevator Cap

05/10/2017

Endoscopy specialist, Pentax Medical Europe has gained CE mark approval for its new duodenoscope with a Disposable Elevator Cap – the DEC™ Duodenoscope.

More...

FDA Approval and U.S. Launch of Medtronic’s New Chronic Intractable Pain Platform

26/09/2017

Medtronic plc has gained FDA approval and is now initiating the U.S. launch of its Intellis™ platform for the management of certain types of chronic intractable pain.

More...

NICE backs use of Opdivo for lung cancer

26/09/2017

Bristol-Myers Squibb’s Opdivo is being recommended by the National Institute for Health and Care Excellence to treat a certain form of lung cancer on the NHS in England, via the Cancer Drugs Fund.

More...

First biotech emerges from Garabedian’s accelerator armed with $10M, plans to tackle autoimmune diseases

26/09/2017

Chris Garabedian’s accelerator has spawned its first biotech. The startup, Landos Biopharma, has secured the support of the ex-Sarepta CEO’s Xontogeny and $10 million from Perceptive Advisors to take a LANCL2-targeted treatment for inflammatory bowel disease (IBD) into the clinic.

More...

FDA approves first cancer biosimilar

20/09/2017

The US Food and Drug Administration has approved Amgen’s Mvasi (bevacizumab-awwb) as a biosimilar to Roche/Genentech’s Avastin (bevacizumab) for the treatment of multiple types of cancer, making it the first biosimilar approved in the country for the treatment of cancer.

More...

Abbott's flash glucose monitor to be made available on NHS

18/09/2017

Abbott's FreeStyle Libre – a flash glucose monitor that allows diabetes patients to track their blood sugar without pricking – will be reimbursed by the NHS from 1 November, subject to local health economy approval.

More...

U.S. 510(K) Clearance for Adherium’s Smartinhaler for AstraZeneca’s Symbicort Aerosol

08/09/2017

The U.S. FDA has cleared Adherium’s new SmartTouch for Symbicort® inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler.

More...

Bicycle Therapeutics could net over $400m in haemophilia deal

08/09/2017

Bicycle Therapeutics has teamed up with another biotech firm in a bid to tackle haemophilia and sickle cell disease in a deal which could net it over $400m.

More...

As Britain tops global university rankings, we must get Brexit right to stay there

06/09/2017

The Times Higher Education World University Rankings have, for the first time, named Oxford and Cambridge as the world’s two top universities. ABPI’s new Head of Education and Academic Liaison, Andrew Croydon, says this latest news adds to the weight of evidence that any Brexit deal should secure the UK’s access to the best science talent and research projects around the world.

More...

Swedish researchers build new tool to test coronary artery disease risk

05/09/2017

Researchers from Uppsala University in Sweden have built a new tool to identify patients who are at high-risk of coronary artery disease and could benefit from new, intensive preventive treatments.

More...

Tox prompts Janssen to drop MacroGenics' cancer antibody

04/09/2017

Janssen is ending a license deal with MacroGenics for duvortuxizumab, a CD19- and CD3-targeting drug for B-cell malignancies it paid $125 million upfront for in 2014, but isn’t severing ties with the biotech entirely.

More...

Report lays out new strategy for UK life sciences

04/09/2017

Industry-led plans to breathe new life into the UK’s £64-billion life sciences sector have been unveiled alongside details of £160 million in government funding to fuel progress in the field.

More...

Boosting immunotherapy by targeting cells’ recycling centers

30/08/2017

A subpopulation of cells in the immune system called CD8+ T cells are vital for the proper functioning of both vaccines and cancer immunotherapy treatments. When these cells divide, they become one of two types of pathogen-destroying soldiers: those that kill right away or those that remember the offender and provide long-term protection. Finding a way to boost the second variety of immune cells, called “memory” CD8+ T cells, could improve both vaccines and immunotherapies.

More...

Convenient Blood Test Detects Circulating DNA to Identify Recurrence of Tumors

30/08/2017

QIAGEN and colorectal cancer diagnostics company Clinical Genomics, tell us they have implemented the PAXgene® Blood ccfDNA Tube* sample collection in Clinical Genomics’ Colvera™ colorectal cancer (“CRC”) recurrence assay.

More...

Novartis breast cancer drug Kisqali wins EU approval

30/08/2017

Novartis has announced the launch of its new breast cancer drug Kisqali in the UK today following a green light from European regulators.

More...

100,000th Smartinhaler™ for Adherium

23/08/2017

Adherium Limited has recently manufactured and sold it’s 100,000th Smartinhaler™.

More...

James Mullen backs Vicarius’ $22M series A to equip ex-Biogen, Elan team to offer U.S. biotechs a route to Europe

23/08/2017

James Mullen has teamed up with colleagues from his days leading Biogen to help U.S. biotechs bring drugs to market in Europe. The resulting startup has raised CHF 21 million ($22 million) to get off the ground—and plans to return for about 10 times that once its business gets up to speed.

More...

Pfizer berates NICE over ALL drug decision

23/08/2017

Pfizer has said it is "very disappointed" by NICE’s decision to not recommend inotuzumab ozogamicin as a treatment for acute lymphoblastic leukaemia (ALL) – and that it believes NICE “inappropriately assessed the value of the medicine in making their determination of cost-effectiveness, using assumptions that are inconsistent with previous appraisals of other medicines in this disease area”.

More...

Celgene drops Sutro buyout option and refocuses deal on 4 I-O programs, freeing partner to pursue new alliances, IPO

11/08/2017

Celgene and Sutro Biopharma have revised the terms of the immuno-oncology pact they entered into in 2014. The reshuffle sees Celgene secure a stake in four assets that are advancing toward the clinic and opportunities to invest in Sutro at the expense of its option to buy the biotech outright.

More...

£2m UK consortium to tackle gene therapy

11/08/2017

A new consortium, led by Oxford BioMedica, will embark on a two-year, £2 million project focused on gene and cell therapy manufacturing.

More...

FDA clears AUM’s diagnostic cardiovascular device

11/08/2017

The US Food and Drug Administration (FDA) has cleared AUM Cardiovascular’s acoustic and electrocardiogram (ECG) device called CADence to aid detection of physiological and pathological heart murmurs.

More...

Silverstein-backed startup will test gene therapy for Parkinson's

10/08/2017

Regenxbio has joined forces with investment firm OrbiMed and a new nonprofit foundation to create Prevail Therapeutics, a startup focused on new biologics and gene therapies for Parkinson's disease (PD).

More...

LimFlow Pilot Study Yields Hope for “Desert Foot”

10/08/2017

A newly published pilot study into the LimFlow pDVA system suggests it offers an alternative option for the “desert foot.”

More...

Diabetes prescriptions rocket 80 percent in a decade

08/08/2017

Growth in prescriptions for diabetes medicines is exceeding the rise in overall prescribing, according to new figures from NHS Digital.

More...

J&J Unveils New Neurovascular Business Name

02/08/2017

Sitting under the DePuy umbrella, Johnson & Johnson Medical Devices Companies has launched a new neurovascular business, to be called CERENOVUS.

More...

New hepatitis C therapies approved in Europe

02/08/2017

Patients with hepatitis C in Europe could soon gain access to two new pan-genotypic treatment options after the European Commission issued approval for AbbVie’s Maviret and Gilead’s Vosevi following an accelerated review.

More...

3 Things In Biotech You Should Learn Today:

02/08/2017

Summary AstraZeneca and Merck join forces in PARP inhibition.

More...

Gilead’s new HIV therapy under EU review

20/07/2017

European regulators are now reviewing Gilead’s fixed-dose combination of bictegravir (BIC), emtricitabine and tenofovir alafenamide as a treatment for HIV-1 infection.

More...

Breath sample cancer detection trials in Cambridge to widen

17/07/2017

Cambridge scientists will widen a cancer clinical trial to see if breath samples can be used to detect cancer in its early stages.

More...

GSK picks third target in Immunocore discovery deal

15/07/2017

GlaxoSmithKline has selected a third target in its collaboration with Oxford, UK-based Immunocore to discover multiple novel targets in cancer not addressable with antibody-based technologies.

More...

Novartis bags first-line approval for Zykadia

13/07/2017

The European Commission has expanded the scope of Novartis’ Zykadia to include the first line treatment of patients with non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive.

More...

LifeArc teams up with UK defence lab and Canada’s CDRD

11/07/2017

LifeArc, the UK medical research charity previously known as MRC Technology, is working alongside the government’s Defence Science and Technology Laboratory and Canada’s Centre for Drug Research and Development (CDRD) to identify new antibacterial drug targets.

More...

GSK signs drug discovery pact with AI group Exscientia

09/07/2017

GlaxoSmithKline has signed a drug discovery pact with Dundee, UK-based artificial intelligence (AI) group Exscientia focused on multiple therapeutic areas.

More...

EU nod for Pfizer’s Besponsa

07/07/2017

Pfizer’s antibody drug conjugate Besponsa has become the first to be approved by regulators in Europe to treat some adults with the rare, aggressive cancer acute lymphoblastic leukaemia (ALL).

More...

MPs keen for close collaboration with EMA post Brexit

05/07/2017

British MPs say they are keen to secure a close working relationship with the European Union on drug regulation post Brexit to protect patient health and investment in the UK’s life sciences sector.

More...

Sandoz launches MabThera, Enbrel biosimilars in the UK

03/07/2017

Novartis group Sandoz has launched two new biosimilars across the UK potentially expanding access to biologic treatments for a range of inflammatory conditions and blood cancers.

More...

Ethicon’s New Power Stapler Delivers Control and Precision for Complex Surgeries

29/06/2017

J&J’s Ethicon has announced the launch of its ECHELON FLEX™ GST System (45mm) across Europe.

More...

Pfizer starts work on $236M biotherapeutics facility in Missouri

29/06/2017

Pfizer's biologic, vaccine and gene therapy researchers should have a new headquarters in mid-2019, now that construction work has started at a site in Chesterfield, Missouri.

More...

Joint expanded portfolio to provide integrated and seamless products and application services

29/06/2017

At the 17th Quadrennial Meeting of the World Society for Stereotactic and Functional Neurosurgery (WSSFN, June 26-29), Elekta (EKTA-B.ST) and Brainlab announced an agreement according to which Brainlab will be the authorized distributor of Elekta's stereotactic solutions for neurosurgery in selected markets.

More...

Novartis’ eye drug on par with Eylea but with fewer injections

21/06/2017

Novartis’ eye drug brolucizumab has been proven in trials to be non-inferior to Regeneron/Bayer’s Elyea in treating vision loss in patients with neovascular age-related macular degeneration (nAMD), but with fewer injections than its rival.

More...

3D-printed patch grows healthy blood vessels in mice, could treat ischemia

21/06/2017

A Boston University-led team has created a cell-infused 3D-printed patch that could become a new treatment option for challenging cases of ischemia.

More...

Cell Medica buys clinical-phase WT1-TCR cell therapy

21/06/2017

Cell Medica has bought Catapult Therapy TCR for its clinical-phase WT1 T-cell receptor (TCR) cell therapy. Catapult Therapy TCR developed the therapy as a treatment for blood cancers, but Cell Medica thinks it can retool it to take out solid tumors.

More...

Novartis’ CAR-T shows durable response in lymphoma patients

08/06/2017

Novartis’ closely-watched CTL019 has elicited a strong response in cancer patients taking the experimental CAR-T cell therapy in a mid-stage trial.

More...

Eko Devices gets FDA nod for its DUO digital stethoscope and ECG combo

08/06/2017

The FDA has cleared Eko Devices’ portable cardiac device that combines a digital stethoscope with electrocardiogram (ECG), allowing cardiologists and patients to better monitor heart disease, the company said.

More...

Johnson & Johnson’s $30B buyout suffers setback as Actelion antibiotic fails in one phase 3, succeeds in another

08/06/2017

Actelion has posted mixed late-phase data on its antibiotic cadazolid. The drug, which Johnson & Johnson is set to acquire in its $30 billion (€27 billion) takeover of Actelion, failed to match an old antibiotic in one study despite holding its own in another identical trial.

More...

Isansys Lifecare opens European headquarters in Brandenburg-Berlin Cluster

08/06/2017

Oxford, UK, 7th June, 2017:  Isansys Lifecare, the leader in new generation wireless patient monitoring systems, today announces the establishment of Isansys Lifecare Europe GmbH.

More...

Devices Aim to Identify Those “At Risk” of OIRD

05/06/2017

Medtronic hopes its new study will establish a role for pulse oximetry and capnography in patients on opioid medication.

More...

EU approves Opdivo for bladder cancer

05/06/2017

Bristol-Myers Squibb’s Opdivo has picked up approval for its eighth indication in Europe, having won clearance for the treatment of a subset of patients with metastatic urothelial carcinoma (mUC).

More...

UK’s F-star signs new deal with Merck

05/06/2017

Cambridge, UK-based F-star has signed a new collaboration with Merck under which the drug giant has the option to develop and commercialise five of its bispecific immuno-oncology antibodies.

More...

Cambridge life sciences firm Bicycle Therapeutics raises £40m

01/06/2017

Cancer drug firm Bicycle Therapeutics has raised £40m to help develop drug candidates to treat cancer.

More...

Horizon Discovery Group on 'path to profit'

01/06/2017

Horizon's CEO says he’s happy with the company’s “robust” revenue growth in 2016.

More...

UK set to become third global hub for biosciences as investment booms

31/05/2017

The UK is the world’s third largest global hub for innovation and development in the biosciences sector, new research has found.

More...

Iterum bags $65M for phase 3 trial of ex-Pfizer antibiotic

19/05/2017

Iterum has completed a $65 million (€58 million) Series B to equip it to take its antibiotic sulopenem through phase 3. The financing moves the total raised by the Irish biopharma company since it emerged last year armed with an antibiotic developed by Pfizer past the $100 million mark.

More...

FDA panel backs TransMedics’ lung transportation device

19/05/2017

The FDA’s Gastroenterology-Urology Devices Panel voted favorably on TransMedics’ perfusion system for the transportation of lungs for transplant.

More...

ARM wants to put a microchip in your brain

19/05/2017

Microchips get everywhere these days, and now ARM has partnered with an American university to try and find ways of putting one into your brain.

More...

Solar powered torch invented by Cambridge University students

19/05/2017

It may not sound like the most useful of devices, but a solar-powered 'torch' was one of the prize winners at Cambridge University Entrepreneurs' business plan competition.

More...

Pfizer doubles down on gene therapy pipeline with $70M Sangamo buy-in

15/05/2017

After deals and acquisitions with Spark Therapeutics and Bamboo, Pfizer is once again looking to bolster its rare and gene therapy pipeline as it outlines a new drug pact with Sangamo.

More...

Boston Scientific gets FDA nod for long-life cardiac implant

15/05/2017

Boston Scientific has received FDA approval for its Resonate line of high-voltage cardiac devices. The regulatory nod clears Boston Scientific to start selling devices it thinks can overcome reticence among physicians to use multipoint pacing products by diminishing concerns about battery life.

More...

X-Ray Capsule Endoscope Passes Manufacturing Tests

15/05/2017

Colorectal capsule innovator, Check-Cap Ltd., together with collaborator GE Healthcare, tell us they’ve achieved an important initial milestone in the development of high volume, X-ray capsule manufacturing capabilities.

More...

Samsung Launches New Ultrasound Systems

15/05/2017

Samsung is unveiling its new HS50 and HS60 ultrasound systems at the American College of Obstetricians and Gynecologists annual meeting in San Diego from May 6-9, 2017.

More...

Guardant gets $360M to sequence 1M cancer patients

15/05/2017

Guardant Health has raised $360 million to sequence the tumor DNA of 1 million cancer patients in the next five years. The SoftBank-led megaround positions the cancer blood test pioneer to push ahead with the sequencing initiative while expanding globally and stepping up its early detection R&D program.

More...

Why AstraZeneca's share price rocketed last week

15/05/2017

AstraZeneca's share price went up five per cent Friday morning (12th May) with news of positive results in a Phase III cancer drug trial.

More...

Cambridge University scientists giving hope to lung disease patients

15/05/2017

Cambridge University spin-out Z Factor hopes its treatment for lung disease will have the, er, X factor after raising £7m to help get new drugs to needy patients.

More...

A £35m new home for Cambridge life sciences firms

26/04/2017

New buildings to house up-and-coming Cambridge life sciences firms are to be constructed thanks to a £35m alliance between two of the city's research parks.

More...

Back to the Future star's foundation funds Cambridge firm's Parkinson's research

26/04/2017

Movie star Michael J Fox is backing the work of a Cambridge life sciences firm looking into a new treatment for Parkinson’s disease.

More...

Medivir posts lymphoma data, guns to get into phase 3

07/04/2017

Medivir has posted data from a phase 2 trial of its histone deacetylase (HDAC) inhibitor in patients with cutaneous T-cell lymphoma (CTCL). One regimen of the treatment triggered responses in 40% of subjects, a finding that has encouraged the Swedish pharmaceutical company to push ahead with plans to start a phase 3 trial later this year.

More...

Novocure's device-chemo combo boosts survival in pancreatic cancer

07/04/2017

Novocure, which markets a wearable device that treats brain cancer, unveiled positive survival data for the phase 2 pilot trial of its noninvasive therapy in patients with pancreatic cancer. The treatment was given alongside two chemotherapy drugs.

More...

Biotech high-fliers Abzena want to raise £25m

07/04/2017

Abzena is hoping to raise another £25m as it continues its bid for world domination.

More...

Australia’s Bionic Vision picks up $18M for ‘bionic eye’

07/04/2017

Bionic Vision Technologies raised AU$23.5 million ($18 million), which will go toward the development and commercialization of its device to restore vision to the blind.

More...

Could these companies unlock biology's potential?

07/04/2017

A new partnership could help unlock the potential of biology and address many of the challenges facing the modern world.

More...

AstraZeneca could slash £2bn R&D budget over NHS spending cap

27/03/2017

AstraZeneca says cost-saving plans for NHS could cause it to cut its £2bn-a-year R&D spend in the UK.

More...

Major pancreatic cancer study launched

27/03/2017

A new pancreatic cancer project has been launched to find ways to speed up scientific discovery to improve the survival rates of patients.

More...

More Texas Success for UK MedTech Companies

21/03/2017

A pioneering iPad case that enables clinical staff and surgeons to use iPads in sterile environments will soon be available in Texas. FlipPad® protects medical practitioners and patients from the risk of healthcare associated infections (HCAI) such as Norovirus and C-Difficile.

More...

Another Cambridge cluster biotech firm is snapped up by Americans

20/03/2017

A Newmarket life sciences supplier has been purchased by an American firm.

More...

'Huge advance' in fighting world's biggest killer

17/03/2017

An innovative new drug can prevent heart attacks and strokes by cutting bad cholesterol to unprecedented levels, say doctors.

More...

Cambridge firm Astex's joy at breast cancer treatment approval

17/03/2017

Astex Pharmaceuticals is celebrating after a breast cancer treatment it worked on was granted approval in the US.

More...

£3.5m to help Abzena cut heart attack and stroke risk

07/03/2017

Abzena and a leading university have received a £3.5m grant to develop a novel therapy for a disease which leaves patients at risk of a stroke or heart attack.

More...

£8m for Cambridge firm that can diagnose diseases in days

07/03/2017

Congenica has raised £8 million in a new funding round that will drive international expansion of its genome analysis business.

More...

Corin Launches FX Solutions Humelock Reverse Shoulder in U.S.

02/03/2017

European orthopaedic device comapny, Corin Group is to launch the Humelock Reversed Shoulder System in the U.S., Germany and U.K. Humelock is used to treat patients with both a massive rotator cuff tear and a severe form of shoulder arthritis.

More...

FDA clears St. Jude's latest FFR-measuring guidewire for coronary artery disease

24/02/2017

St. Jude Medical launched its newly FDA-cleared guidewire that measures fractional flow reserve. It is designed to improve percutaneous coronary intervention procedures in patients with narrowed coronary arteries.

More...

With FDA nod, Biotronik debuts first coronary stent in U.S.

24/02/2017

Biotronik has received FDA approval for a bare-metal stent designed to treat coronary artery disease. It is the company’s first coronary stent to hit the U.S. market.

More...

Cancer startup PMV Pharma gains impressive $74M B round

24/02/2017

New Jersey oncology biotech PMV Pharma has seen a healthy $74 million in funding from its Series B with help from InterWest Partners, Osage University Partners, Topspin Biotech Fund (which led this round), and its Series A lead investor OrbiMed.

More...

FDA clears 7SBio's 'virtually painless' blood collection device

24/02/2017

Seventh Sense Biosystems (7SBio) picked up an FDA nod for its “push-button” blood collection device, specifically to test the HbA1c levels in patients with diabetes and prediabetes. The company plans to add more assays for use with the device.

More...

Stemcell specialists are latest addition to Cambridge life sciences cluster

21/02/2017

The latest addition to the Cambridge life sciences cluster is a firm that provides reagents and tools to support researchers.

More...

Medtronic’s Signia™ Stapling System Adapts to Tissue Variability

21/02/2017

Medtronic plc has announced the launch of its Signia™ Stapling System which rather cleverly adapts to variability in tissue thickness.

More...

Mitotech eyes novel approach to treating Dry Eye Disease

14/02/2017

An aging population, an ever increasing amount of time viewing digital devices and a growing trend in eye diseases are all factors expected to fuel a global increase in Dry Eye Disease. Currently, there are about 16 million people in the U.S. alone suffering from the condition, which is quickly becoming a common malady.

More...

Medtronic adds transradial diagnostic catheters to coronary product line

14/02/2017

Medtronic unveiled three new additions to its coronary portfolio Monday—a transradial diagnostic catheter and accompanying transradial devices to facilitate the treatment of coronary artery disease via the radial artery in the wrist.

More...

FDA Approval for First Balloon Expandable Stent Graft for Use in the Iliac Artery

06/02/2017

W. L. Gore & Associates tells us its GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) has received U.S. FDA approval for treatment of de novo or restenotic lesions found in iliac arteries, including lesions at the aortic bifurcation.

More...

J&J invests in Caelus, pens pacts to grow microbiome R&D

06/02/2017

Johnson & Johnson has unveiled a clutch of deals intended to grow its presence in the microbiome sector. The agreements will give J&J a stake in microbiota drug development shop Caelus Health—and links to DayTwo and the Weizmann Institute of Science to bolster its own activities.

More...

Abbott’s tiny wireless pacemaker is now MRI-compatible

06/02/2017

The FDA approved MRI-conditional labeling for Abbott’s tiny wireless pacemaker, making it the smallest and longest-lasting MRI-compatible device of its kind. The new labeling also applies to a pacing lead.

More...

Government must "learn from Cambridge" as it forms industrial strategy

30/01/2017

The Government must look to Cambridge as an example for the rest of the country when it prepares its new industrial strategy.

More...

Shark-inspired drug may help treat fibrosis, researchers say

30/01/2017

Australian scientists hope a drug that mimics part of a shark's immune system may help treat an incurable lung disease.

More...

Philips developing augmented-reality navigation for minimally invasive surgeries

18/01/2017

Philips revealed Thursday that it is developing a new surgical system that uses augmented reality to guide surgeons performing open and minimally invasive spinal surgery. The system combines external and internal images of the patient in real time to guide these procedures.

More...

AstraZeneca delays PD-L1 data in rejig of phase 3 program

18/01/2017

AstraZeneca has pushed back the estimated completion date for the phase 3 trial of its PD-L1 drug, a first-line treatment for non-small cell lung cancer (NSCLC). Progression-free survival data are now due to drop in the middle of this year, with an overall survival readout set to follow by 2018 at the latest.

More...

J&J teams with Orthocell on regenerative stem cell program

18/01/2017

Johnson & Johnson’s DePuy Synthes Products is collaborating with Orthocell on development of a stem cell-based approach to the regeneration of tendons. The partners are due to start a clinical trial of the candidate Ortho-ATI this quarter.

More...

SuliquaTM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes

18/01/2017

Sanofi announced today that the European Commission has granted marketing authorization in Europe for SuliquaTM, the once-daily titratable fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of adults with type 2 diabetes. Suliqua is authorized for use in combination with metformin to improve glycemic control when this has not been provided by metformin alone or metformin combined with another oral glucose lowering medicinal product or with basal insulin.

More...

Novartis, Pfizer join with Big Biopharma peers to create tech standards that streamline how HCPs access information

16/01/2017

Novartis, Pfizer and four more major biopharma companies have teamed with cloud computing player Veeva Systems to make it easier for healthcare professionals to access information about drugs. The partners are creating a single login for HCPs to use to access all online content, instead of having to enter a different username for each company.

More...

OxSonics bags $11M to take ultrasound tech into the clinic

16/01/2017

OxSonics and its sister company have raised $11 million to take ultrasound-based technologies into clinical development. The Series B will support development of technology that rapidly expands and collapses bubbles to improve drug delivery to solid tumors or treat chronic low back pain.

More...

U.S. Launch and First Commercial Use of Abbott’s New EnSite™ Precision Cardiac Mapping System

13/01/2017

Abbott has announced the U.S. launch and the first commercial uses of the new EnSite Precision™ cardiac mapping system and Advisor™ FL Circular Mapping Catheter, Sensor Enabled™ to map cardiac arrhythmias during ablation treatments.

More...

Why Sareum is in the money again

13/01/2017

Sareum is sharing in a $2m mile-stone payment stemming from its Chk1 inhibitor cancer drug candidate.

More...

Abcam making big progress in China

11/01/2017

Life sciences giant Abcam expects to report strong growth in the Chinese market when it delivers its interim results.

More...

Microsoft's Bill Gates awards $9m grant to Cambridge firm seeking HIV cure

10/01/2017

Bill Gates is pumping $9m into a Cambridge life sciences firm to strengthen its work developing novel treatments and vaccines for infectious diseases including HIV.

More...

Owlstone Medical Announces $11.55M USD (£9.3M GBP) Fundraising

09/01/2017

Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, today announced that it has successfully raised $11.55 million USD (£9.3 million GBP) financing. The investment round was led by existing investors, and will be used to commercially launch the company’s breath biomarker R&D services, including the opening of a new high volume clinical facility, and to fund ongoing clinical trials in lung and colon cancer screening. The funding follows the original investment of $7 million (£4.9 million) that spun Owlstone Medical out in June 2016.

More...

New year, new deals: J&J partners on 3D-printed meniscus, sleep coaching

09/01/2017

Johnson & Johnson Innovation unveiled 15 new collaborations, boosting its total deal count past 300. Most of the tie-ups surround drug discovery and development, but a few fall on the medical device side—including 3D printing an artificial meniscus and creating a personalized sleep coaching system for babies.

More...

How a licensing deal could net Babraham's Abzena $35m

03/01/2017

Abzena has received an early Christmas present with the news that it could be in line for $35m after signing a licensing agreement.

More...

Cambridge research could lead to new treatments for vascular disease

22/12/2016

Cambridge University is teaming up with King’s College London and a pharmaceutical firm to repurpose drugs in the hope that they can treat vascular disease.

More...

Megamerger era may be over, but M&A spend still hovers around bigger deals

22/12/2016

Following 2014’s summer of “med tech merger mania,” 2015 was a record-breaking year for med tech M&A--even if we exclude the $50 billion Medtronic-Covidien tie-up, 2015 still beats every other year in the past decade. But what of 2016?

More...

Multiple sclerosis drug 'a landmark'

22/12/2016

A drug that alters the immune system has been described as "big news" and a "landmark" in treating multiple sclerosis, doctors and charities say.

More...

MicroPort invests in Lombard, lands rights to stent grafts

22/12/2016

MicroPort Scientific has invested $15 million in Lombard Medical as part of a deal that gives it rights to stent grafts in China and Brazil. The pact gives Lombard a partner capable of commercializing its Aorfix and Altura stent grafts in key global markets, plus an infusion of capital and component supply pact.

More...

This AstraZeneca drug could replace chemotherapy as standard lung cancer treatment

22/12/2016

An AstraZeneca drug could replace chemotherapy as the new standard treatment for lung cancer after it performed well in a trial.

More...